Keywords: baxter/halozyme, see, good, data, subq, plus, hylenex
Baxter/Halozyme see good data on SubQ plus Hylenex
Article | 20 February 2006
Baxter Healthcare Corp says that, according to its INFUSE-LR clinical trial, subcutaneous (Sub-Q) infusion (hypodermoclysis) followed with fellow USA-based Halozyme ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
